Enveric Biosciences (ENVB) Total Debt Growth (1y) (2016 - 2021)
Enveric Biosciences (ENVB) Total Debt Growth (1y) (2016 - 2021) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.10% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 12.42% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -57.72% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 3.78% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -94.03% |
| Sep 30, 2020 | -45.34% |
| Mar 31, 2020 | 8.74% |
| Dec 31, 2019 | 247.43% |
| Sep 30, 2019 | -4.71% |
| Mar 31, 2019 | -2.48% |
| Dec 31, 2018 | -99.88% |
| Sep 30, 2018 | 81.84% |
| Jun 30, 2018 | 87.95% |
| Mar 31, 2018 | -13.78% |
| Dec 31, 2017 | 12.08% |
| Sep 30, 2017 | 26.47% |
| Jun 30, 2017 | -68.37% |
| Mar 31, 2017 | 895.99% |
| Dec 31, 2016 | -25.83% |
| Sep 30, 2016 | 526.67% |